Lake Street lowered the firm’s price target on Sight Sciences (SGHT) to $3 from $5 and keeps a Hold rating on the shares after the company reported preliminary Q4 revenue that fell short of the consensus forecast. The Q4 shortfall resulted from the mid-November local coverage determinations disallowing combination MIGS procedures, notes the analyst, who eventually expects this to headwind to subside and for Sight to return to growth. However, the firm thinks the headwinds will persist through at least the first half of the year.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences sees Q4 revenue $18.9M-19.1M, consensus $20.29M
- Sight Sciences study demonstrates benefits of OMNI system for managing POAG
- Sight Sciences does BIA of TearCare to treat MGD-associated DED in US
- Sight Sciences price target lowered to $4.60 from $5.80 at Citi
- Sight Sciences initiated with a Buy at UBS